JP5054525B2 - 腎疾患および腎損傷の早期発見のための方法 - Google Patents
腎疾患および腎損傷の早期発見のための方法 Download PDFInfo
- Publication number
- JP5054525B2 JP5054525B2 JP2007527645A JP2007527645A JP5054525B2 JP 5054525 B2 JP5054525 B2 JP 5054525B2 JP 2007527645 A JP2007527645 A JP 2007527645A JP 2007527645 A JP2007527645 A JP 2007527645A JP 5054525 B2 JP5054525 B2 JP 5054525B2
- Authority
- JP
- Japan
- Prior art keywords
- ngal
- serum
- injury
- level
- acute
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 64
- 230000006378 damage Effects 0.000 title claims abstract description 54
- 238000001514 detection method Methods 0.000 title claims abstract description 35
- 208000017169 kidney disease Diseases 0.000 title abstract description 3
- 210000002966 serum Anatomy 0.000 claims abstract description 135
- 230000005779 cell damage Effects 0.000 claims abstract description 79
- 208000037887 cell injury Diseases 0.000 claims abstract description 79
- 206010061481 Renal injury Diseases 0.000 claims abstract description 27
- 230000003589 nefrotoxic effect Effects 0.000 claims abstract description 14
- 231100000381 nephrotoxic Toxicity 0.000 claims abstract description 14
- 208000009304 Acute Kidney Injury Diseases 0.000 claims description 91
- 208000033626 Renal failure acute Diseases 0.000 claims description 91
- 201000011040 acute kidney failure Diseases 0.000 claims description 91
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 70
- 210000003734 kidney Anatomy 0.000 claims description 56
- 208000012998 acute renal failure Diseases 0.000 claims description 55
- 230000000302 ischemic effect Effects 0.000 claims description 38
- 238000011282 treatment Methods 0.000 claims description 37
- 229940109239 creatinine Drugs 0.000 claims description 35
- 208000014674 injury Diseases 0.000 claims description 24
- 208000037806 kidney injury Diseases 0.000 claims description 24
- 210000000440 neutrophil Anatomy 0.000 claims description 24
- 208000027418 Wounds and injury Diseases 0.000 claims description 21
- 230000001154 acute effect Effects 0.000 claims description 18
- 210000004369 blood Anatomy 0.000 claims description 16
- 239000008280 blood Substances 0.000 claims description 16
- 238000001356 surgical procedure Methods 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 231100000765 toxin Toxicity 0.000 claims description 7
- 239000003053 toxin Substances 0.000 claims description 7
- 102000019298 Lipocalin Human genes 0.000 claims description 5
- 108050006654 Lipocalin Proteins 0.000 claims description 5
- 238000007675 cardiac surgery Methods 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 4
- 206010040047 Sepsis Diseases 0.000 claims description 4
- 238000003556 assay Methods 0.000 claims description 3
- 230000006872 improvement Effects 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 230000008733 trauma Effects 0.000 claims description 3
- 238000007631 vascular surgery Methods 0.000 claims description 3
- 208000005156 Dehydration Diseases 0.000 claims description 2
- 102000013382 Gelatinases Human genes 0.000 claims description 2
- 108010026132 Gelatinases Proteins 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 230000018044 dehydration Effects 0.000 claims description 2
- 238000006297 dehydration reaction Methods 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 238000013130 cardiovascular surgery Methods 0.000 claims 2
- 210000004351 coronary vessel Anatomy 0.000 claims 2
- 230000004064 dysfunction Effects 0.000 claims 1
- 102000013519 Lipocalin-2 Human genes 0.000 abstract description 185
- 108010051335 Lipocalin-2 Proteins 0.000 abstract description 185
- 239000000090 biomarker Substances 0.000 abstract description 110
- 108090000623 proteins and genes Proteins 0.000 abstract description 23
- 102000004169 proteins and genes Human genes 0.000 abstract description 19
- 239000003550 marker Substances 0.000 abstract description 11
- 239000003814 drug Substances 0.000 abstract description 8
- 208000001647 Renal Insufficiency Diseases 0.000 abstract description 7
- 201000006370 kidney failure Diseases 0.000 abstract description 7
- 210000005233 tubule cell Anatomy 0.000 abstract description 6
- 206010063897 Renal ischaemia Diseases 0.000 abstract description 4
- 210000005234 proximal tubule cell Anatomy 0.000 abstract description 4
- 108091005804 Peptidases Proteins 0.000 abstract description 3
- 239000004365 Protease Substances 0.000 abstract description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract description 3
- 238000012544 monitoring process Methods 0.000 abstract description 3
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 abstract description 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 2
- 230000001086 cytosolic effect Effects 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 230000010024 tubular injury Effects 0.000 abstract 1
- 208000037978 tubular injury Diseases 0.000 abstract 1
- 210000002700 urine Anatomy 0.000 description 56
- 239000000523 sample Substances 0.000 description 43
- 230000002485 urinary effect Effects 0.000 description 30
- 210000004027 cell Anatomy 0.000 description 22
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 20
- 235000018102 proteins Nutrition 0.000 description 17
- 238000002965 ELISA Methods 0.000 description 14
- 238000005259 measurement Methods 0.000 description 14
- 102100034459 Hepatitis A virus cellular receptor 1 Human genes 0.000 description 11
- 101710185991 Hepatitis A virus cellular receptor 1 homolog Proteins 0.000 description 11
- 206010029155 Nephropathy toxic Diseases 0.000 description 11
- 231100000417 nephrotoxicity Toxicity 0.000 description 11
- 230000007694 nephrotoxicity Effects 0.000 description 11
- 230000004044 response Effects 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 238000001262 western blot Methods 0.000 description 11
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 10
- 229960004316 cisplatin Drugs 0.000 description 10
- 229910052742 iron Inorganic materials 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 9
- 208000037906 ischaemic injury Diseases 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 230000006698 induction Effects 0.000 description 8
- 101001023833 Homo sapiens Neutrophil gelatinase-associated lipocalin Proteins 0.000 description 7
- 238000009825 accumulation Methods 0.000 description 7
- 238000013399 early diagnosis Methods 0.000 description 7
- 230000029142 excretion Effects 0.000 description 7
- 102000047202 human LCN2 Human genes 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 210000000981 epithelium Anatomy 0.000 description 6
- 230000000977 initiatory effect Effects 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 108700012359 toxins Proteins 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 5
- 230000003907 kidney function Effects 0.000 description 5
- 231100000637 nephrotoxin Toxicity 0.000 description 5
- 230000008929 regeneration Effects 0.000 description 5
- 238000011069 regeneration method Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 208000035143 Bacterial infection Diseases 0.000 description 4
- 206010063837 Reperfusion injury Diseases 0.000 description 4
- 208000022362 bacterial infectious disease Diseases 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 230000000474 nursing effect Effects 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 230000003827 upregulation Effects 0.000 description 4
- 102000012192 Cystatin C Human genes 0.000 description 3
- 108010061642 Cystatin C Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000029795 kidney development Effects 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 210000000512 proximal kidney tubule Anatomy 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 208000003918 Acute Kidney Tubular Necrosis Diseases 0.000 description 2
- 101150042405 CCN1 gene Proteins 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- 208000002330 Congenital Heart Defects Diseases 0.000 description 2
- 238000009007 Diagnostic Kit Methods 0.000 description 2
- 206010014561 Emphysema Diseases 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102100035405 Neutrophil gelatinase-associated lipocalin Human genes 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 206010038540 Renal tubular necrosis Diseases 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 108010059993 Vancomycin Proteins 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000002612 cardiopulmonary effect Effects 0.000 description 2
- 230000011712 cell development Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 208000028831 congenital heart disease Diseases 0.000 description 2
- 239000002872 contrast media Substances 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 231100000268 induced nephrotoxicity Toxicity 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 210000000885 nephron Anatomy 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000000861 pro-apoptotic effect Effects 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000008085 renal dysfunction Effects 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- 210000005239 tubule Anatomy 0.000 description 2
- 238000007473 univariate analysis Methods 0.000 description 2
- 229960003165 vancomycin Drugs 0.000 description 2
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 2
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 1
- 229930183010 Amphotericin Natural products 0.000 description 1
- QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 1
- 206010063836 Atrioventricular septal defect Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 101000609447 Beet necrotic yellow vein virus (isolate Japan/S) Protein P25 Proteins 0.000 description 1
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102100031171 CCN family member 1 Human genes 0.000 description 1
- 101710137355 CCN family member 1 Proteins 0.000 description 1
- 241001164374 Calyx Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000003670 Carboxypeptidase B Human genes 0.000 description 1
- 108090000087 Carboxypeptidase B Proteins 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010009192 Circulatory collapse Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 102000005889 Cysteine-Rich Protein 61 Human genes 0.000 description 1
- 108010019961 Cysteine-Rich Protein 61 Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000023281 Fallot tetralogy Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 101000881168 Homo sapiens SPARC Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 208000035478 Interatrial communication Diseases 0.000 description 1
- 108090000171 Interleukin-18 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 206010069384 Ischaemic nephropathy Diseases 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 206010023424 Kidney infection Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 101001023834 Mus musculus Neutrophil gelatinase-associated lipocalin Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 101000621511 Potato virus M (strain German) RNA silencing suppressor Proteins 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- 206010048988 Renal artery occlusion Diseases 0.000 description 1
- 108091006649 SLC9A3 Proteins 0.000 description 1
- 102100037599 SPARC Human genes 0.000 description 1
- 102000052126 Sodium-Hydrogen Exchangers Human genes 0.000 description 1
- 102100030375 Sodium/hydrogen exchanger 3 Human genes 0.000 description 1
- 108091006672 Sodium–hydrogen antiporter Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 201000003005 Tetralogy of Fallot Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 208000001910 Ventricular Heart Septal Defects Diseases 0.000 description 1
- 206010047296 Ventricular hypoplasia Diseases 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 229940009444 amphotericin Drugs 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 208000013914 atrial heart septal defect Diseases 0.000 description 1
- 206010003664 atrial septal defect Diseases 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000000981 bystander Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 210000004922 colonic epithelial cell Anatomy 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000000994 contrast dye Substances 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 210000005232 distal tubule cell Anatomy 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008202 epithelial morphogenesis Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 208000018578 heart valve disease Diseases 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000006759 inflammatory activation Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000003093 intracellular space Anatomy 0.000 description 1
- 238000011862 kidney biopsy Methods 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 238000000491 multivariate analysis Methods 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000000101 novel biomarker Substances 0.000 description 1
- 230000005868 ontogenesis Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 210000001948 pro-b lymphocyte Anatomy 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 210000004926 tubular epithelial cell Anatomy 0.000 description 1
- 230000002620 ureteric effect Effects 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 201000003130 ventricular septal defect Diseases 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/82—Translation products from oncogenes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Transplanting Machines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57766204P | 2004-06-07 | 2004-06-07 | |
| US60/577,662 | 2004-06-07 | ||
| US11/096,113 US20050272101A1 (en) | 2004-06-07 | 2005-03-31 | Method for the early detection of renal injury |
| US11/096,113 | 2005-03-31 | ||
| PCT/US2005/019951 WO2005121788A2 (en) | 2004-06-07 | 2005-06-07 | Method for the early detection of renal disease and injury |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008501979A JP2008501979A (ja) | 2008-01-24 |
| JP2008501979A5 JP2008501979A5 (es) | 2011-03-24 |
| JP5054525B2 true JP5054525B2 (ja) | 2012-10-24 |
Family
ID=35449446
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007527645A Active JP5054525B2 (ja) | 2004-06-07 | 2005-06-07 | 腎疾患および腎損傷の早期発見のための方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (7) | US20050272101A1 (es) |
| EP (2) | EP1766395B2 (es) |
| JP (1) | JP5054525B2 (es) |
| CN (1) | CN101027556B (es) |
| AT (1) | ATE488765T1 (es) |
| AU (1) | AU2005253142B2 (es) |
| CA (1) | CA2569599C (es) |
| DE (1) | DE602005024810D1 (es) |
| ES (1) | ES2717900T3 (es) |
| WO (1) | WO2005121788A2 (es) |
Families Citing this family (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100506841C (zh) * | 2003-05-01 | 2009-07-01 | 科内尔研究基金会 | 将分子递送到细胞的方法和载体复合物 |
| US20050272101A1 (en) * | 2004-06-07 | 2005-12-08 | Prasad Devarajan | Method for the early detection of renal injury |
| US7776824B2 (en) * | 2004-05-06 | 2010-08-17 | The Trustees Of Columbia University | NGAL for reduction and amelioration of ischemic and nephrotoxic injuries |
| ES2818028T3 (es) * | 2004-12-20 | 2021-04-09 | Antibodyshop As | Determinación de lipocalina asociada a gelatinasa de neutrófilos (NGAL) como marcador diagnóstico para trastornos renales |
| US20070037232A1 (en) * | 2005-03-31 | 2007-02-15 | Barasch Jonathan M | Detection of NGAL in chronic renal disease |
| EP1931369B1 (en) | 2005-09-16 | 2016-08-17 | Cornell Research Foundation, Inc. | Aromatic-cationic peptide for use in a method for reducing CD36 expression |
| US20080090304A1 (en) * | 2006-10-13 | 2008-04-17 | Barasch Jonathan Matthew | Diagnosis and monitoring of chronic renal disease using ngal |
| US10716749B2 (en) * | 2005-11-03 | 2020-07-21 | Palo Alto Investors | Methods and compositions for treating a renal disease condition in a subject |
| US7662578B2 (en) | 2006-04-21 | 2010-02-16 | Children's Hospital Medical Center | Method and kit for the early detection of impaired renal status |
| US20080090765A1 (en) * | 2006-05-25 | 2008-04-17 | The Trustees Of Columbia University In The City Of New York | Compositions for modulating growth of embryonic and adult kidney tissue and uses for treating kidney damage |
| WO2007137584A1 (en) * | 2006-05-30 | 2007-12-06 | Antibodyshop A/S | Methods and devices for rapid assessment of severity of injury |
| EP2064553B2 (en) † | 2006-08-07 | 2023-06-07 | Antibodyshop A/S | Diagnostic test to exclude significant renal injury |
| WO2008060607A2 (en) * | 2006-11-14 | 2008-05-22 | Biosite Incorporated | Methods and compositions for monitoring and risk prediction in cardiorenal syndrome |
| US8524462B2 (en) | 2006-11-14 | 2013-09-03 | Alere San Diego, Inc. | Methods and compositions for diagnosis and prognosis of renal artery stenosis |
| US8313919B2 (en) * | 2007-03-21 | 2012-11-20 | Bioporto Diagnostics A/S | Diagnostic test for renal injury |
| US20090123946A1 (en) * | 2007-10-19 | 2009-05-14 | Abbott Laboratories | Immunoassays and kits for the detection of ngal |
| US8846036B2 (en) * | 2007-10-19 | 2014-09-30 | Abbott Laboratories | Antibodies that bind to mammalian NGAL and uses thereof |
| EP2235053A1 (en) * | 2007-10-19 | 2010-10-06 | Abbott Laboratories | Glycosylated mammalian ngal and use thereof |
| US20090124022A1 (en) * | 2007-10-19 | 2009-05-14 | Abbott Laboratories | Antibodies that bind to mammalian ngal and uses thereof |
| WO2009059259A2 (en) * | 2007-10-31 | 2009-05-07 | Children's Hospital Medical Center | Detection of worsening renal disease in subjects with systemic lupus erythematosus |
| PL2215481T5 (pl) * | 2007-11-15 | 2017-10-31 | Bioporto Diagnostics As | Zastosowanie diagnostyczne indywidualnych postaci cząsteczkowych biomarkera |
| EP2712620A1 (en) | 2008-02-07 | 2014-04-02 | Cornell University | Methods for Preventing or Treating Insulin Resistance |
| EP2262520B1 (en) * | 2008-02-26 | 2017-05-03 | Cornell University | Compositions for prevention and treatment of renal injury |
| US8592170B2 (en) * | 2008-03-12 | 2013-11-26 | The Trustees Of Columbia University In The City Of New York | High molecular weight Ngal as a biomarker for chronic kidney disease |
| GB0807214D0 (en) * | 2008-04-21 | 2008-05-28 | Belfast Health And Social Care | Biomarkers |
| US7977110B2 (en) * | 2008-06-02 | 2011-07-12 | Children's Hospital Medical Center | Method for distinguishing between kidney dysfunctions |
| US20100122355A1 (en) * | 2008-07-16 | 2010-05-13 | Neal Paragas | Transgenic Reporter Mouse and Method for Use |
| AU2009285550B2 (en) * | 2008-08-28 | 2015-06-18 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| EP2813848A3 (en) * | 2008-08-29 | 2015-03-11 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| EP2347260A4 (en) * | 2008-10-21 | 2012-09-26 | Astute Medical Inc | METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE |
| CN102246035B (zh) * | 2008-10-21 | 2014-10-22 | 阿斯图特医药公司 | 用于诊断和预后肾损伤和肾衰竭的方法和组合物 |
| US20100105150A1 (en) * | 2008-10-24 | 2010-04-29 | Abbott Laboratories | Isolated human autoantibodies to neutrophil gelatinase-associated lipocalin (ngal) and methods and kits for the detection of human autoantibodies to ngal |
| CA2742291A1 (en) * | 2008-11-05 | 2010-05-14 | Abbott Laboratories | Neutrophil gelatinase-associated lipocalin (ngal) protein isoforms enriched from urine and recombinant chinese hamster ovary (cho) cells and related compositions, antibodies, andmethods of enrichment, analysis and use |
| AU2009313189B2 (en) | 2008-11-10 | 2014-10-23 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| US20100124829A1 (en) * | 2008-11-17 | 2010-05-20 | Hon Hai Precision Industry Co., Ltd. | Electrical connector with a printed circuit board mounted thereon |
| WO2010058378A1 (en) | 2008-11-21 | 2010-05-27 | Phadia Ab | Methods, devices and kits for detecting or monitoring acute kidney injury |
| US20110229915A1 (en) * | 2008-11-22 | 2011-09-22 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| US9229010B2 (en) | 2009-02-06 | 2016-01-05 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| EP3244213A1 (en) * | 2009-02-06 | 2017-11-15 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| US20100233740A1 (en) * | 2009-02-12 | 2010-09-16 | Jonathan Barasch | Use of urinary ngal to distinguish kidney disease and predict mortality in subjects with cirrhosis |
| US20100233739A1 (en) * | 2009-02-12 | 2010-09-16 | Jonathan Barasch | Use of urinary ngal to diagnose unilateral and bilateral urinary obstruction |
| US20100331265A1 (en) | 2009-03-20 | 2010-12-30 | Tompkins Ronald G | Methods for the prevention and treatment of burn injuries and secondary complications |
| ES2516717T3 (es) * | 2009-05-26 | 2014-10-31 | Universidad De Salamanca | Proteína activadora de GM2 en orina como marcador de fallo renal agudo o de riesgo de desarrollar fallo renal agudo |
| CN102576011B (zh) | 2009-08-07 | 2014-09-17 | 阿斯图特医药公司 | 用于肾损伤和肾衰竭的诊断及预后的组合物和方法 |
| EP3251686A1 (en) * | 2009-08-12 | 2017-12-06 | Cornell University | Methods for preventing or treating metabolic syndrome |
| US8470784B2 (en) | 2009-08-24 | 2013-06-25 | Stealth Peptides International, Inc. | Methods and compositions for preventing or treating ophthalmic conditions |
| EP2894473B1 (en) * | 2009-08-28 | 2016-09-21 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| JP2013506696A (ja) | 2009-10-05 | 2013-02-28 | コーネル ユニヴァーシティー | 心不全の予防又は処置の方法 |
| WO2011053832A1 (en) * | 2009-10-29 | 2011-05-05 | The Trustees Of Columbia University In The City Of New York | Use of urinary ngal to diagnose sepsis in very low birth weight infants |
| CN102725635B (zh) | 2009-11-07 | 2015-05-20 | 阿斯图特医药公司 | 用于肾损伤和肾衰竭的诊断及预后的方法和组合物 |
| CA2784889C (en) | 2009-12-20 | 2018-06-19 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| DK2666872T3 (en) | 2010-02-05 | 2016-07-25 | Astute Medical Inc | Methods and compositions for the diagnosis and prognosis of renal injury and renal insufficiency |
| NZ705411A (en) * | 2010-02-26 | 2016-06-24 | Astute Medical Inc | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| GB2478520A (en) * | 2010-03-02 | 2011-09-14 | Binding Site Group Ltd | Kidney prognostic assay |
| US20110229921A1 (en) * | 2010-03-18 | 2011-09-22 | Abbott Laboratories | METHODS OF ASSAYING URINARY NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN (uNGAL) IN THE PROGNOSIS OF CADAVERIC KIDNEY TRANSPLANT FUNCTION IN A PATIENT, INCLUDING A PATIENT DIAGNOSED WITH DELAYED GRAFT FUNCTION (DGF), A METHOD OF ASSAYING uNGAL IN THE ASSESSMENT OF RISK OF DGF IN A PATIENT DIAGNOSED WITH EARLY GRAFT FUNCTION (EGF), AND RELATED KITS |
| CN102072960A (zh) * | 2010-03-29 | 2011-05-25 | 武汉生之源生物科技有限公司 | 一种样本中中性粒细胞明胶酶相关脂质运载蛋白的检测方法 |
| WO2011143232A1 (en) * | 2010-05-10 | 2011-11-17 | Westerman Mark E | Markers for acute kidney injury |
| ES2667066T3 (es) | 2010-05-24 | 2018-05-09 | The Trustees Of Columbia University In The City Of New York | Proteínas NGAL mutantes y usos de las mismas |
| EP2397559A1 (en) * | 2010-06-17 | 2011-12-21 | Max-Delbrück-Centrum Für Molekulare Medizin | Stage-specific biomarkers for the diagnosis of acute kidney injury |
| AU2011269775B2 (en) | 2010-06-23 | 2015-01-15 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| IN2012MN02812A (es) | 2010-06-23 | 2015-05-22 | Astute Medical Inc | |
| EP2415461B1 (en) * | 2010-07-24 | 2012-10-31 | Roche Diagnostics GmbH | Stabilization of interleukin 6 in serum based solutions |
| NZ608316A (en) * | 2010-10-07 | 2015-03-27 | Astute Medical Inc | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| CN102243241A (zh) * | 2011-04-07 | 2011-11-16 | 武汉生之源生物科技有限公司 | 一种匀相溶胶颗粒型中性粒细胞明胶酶相关脂质运载蛋白测定试剂盒及其制备方法 |
| CN102253217B (zh) * | 2011-04-07 | 2013-08-07 | 武汉生之源生物科技有限公司 | 一种胶乳颗粒增强型中性粒细胞明胶酶相关脂质运载蛋白检测试剂盒 |
| NL2007112C2 (en) | 2011-07-14 | 2013-01-15 | Brainlabs B V | Novel diagnostic method for diagnosing depression and monitoring therapy effectiveness. |
| KR20140074307A (ko) * | 2011-08-26 | 2014-06-17 | 아스튜트 메디컬 인코포레이티드 | 신장 손상 및 신부전의 진단 및 예후진단을 위한 방법 및 조성물 |
| US20130062516A1 (en) * | 2011-09-09 | 2013-03-14 | Hsien-Shou Kuo | Diganosis of a renal disease by oxygen and hydrogen isotopes in a biological sample |
| KR20140074293A (ko) * | 2011-09-14 | 2014-06-17 | 바스프 에스이 | 신장 독성을 평가하기 위한 수단 및 방법 |
| BR112014006741A2 (pt) * | 2011-09-22 | 2017-03-28 | Univ Los Andes | método para monitorização, diagnóstico e/ou prognóstico de lesão renal aguda no estágio inicial |
| EP3540440B1 (en) | 2011-12-08 | 2022-09-28 | Astute Medical, Inc. | Methods and uses for evaluating renal injury and renal status |
| JP5988199B2 (ja) * | 2012-05-29 | 2016-09-07 | 学校法人順天堂 | ＩｇＡ腎症診断法 |
| GB201210587D0 (en) * | 2012-06-14 | 2012-08-01 | Belfast Health And Social Care Trust | Predictive biomarker |
| WO2014081980A2 (en) | 2012-11-21 | 2014-05-30 | The Trustees Of Columbia University In The City Of New York | Mutant ngal proteins and uses thereof |
| CN107976547B (zh) | 2013-01-17 | 2020-08-25 | 阿斯图特医药公司 | 用于肾损伤和肾衰竭的诊断及预后的方法和组合物 |
| EP3521442B1 (en) * | 2013-07-15 | 2023-05-03 | President and Fellows of Harvard College | Assays for antimicrobial activity and applications thereof |
| CN104198732B (zh) * | 2014-08-28 | 2015-08-19 | 宁波瑞源生物科技有限公司 | 一种中性粒细胞明胶酶相关脂质运载蛋白含量检测试剂盒 |
| CN104849469A (zh) * | 2015-04-16 | 2015-08-19 | 广州市达瑞生物技术股份有限公司 | 一种检测ngal含量的试剂盒及其制备方法 |
| CL2015003047A1 (es) | 2015-10-15 | 2016-06-17 | Univ Chile | Método ex vivo para detectar precozmente injuria renal aguda en pacientes críticos, que comprende la mediciom en una muestra de tres proteinas como biomarcadores, factor de crecimiento fibroblástico 23, klotho y eritropoyetina |
| EP3465201A4 (en) | 2016-06-06 | 2020-08-26 | Astute Medical, Inc. | MANAGEMENT OF ACUTE KIDNEY DAMAGE USING INSULINOMIMETIC GROWTH FACTOR BINDING PROTEIN 7 AND TISSUE METALLOPROTEINASE 2 INHIBITOR |
| WO2018145117A1 (en) | 2017-02-06 | 2018-08-09 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| CN110229214B (zh) * | 2018-03-05 | 2022-03-18 | 四川大学华西医院 | 一种外泌体缓释多肽水凝胶及其制备方法和用途 |
| TW202022379A (zh) * | 2018-10-17 | 2020-06-16 | 日商資生堂股份有限公司 | 檢定根據血液中之肌酸酐含量之腎功能檢查結果之妥當性之方法 |
| US11350887B2 (en) | 2019-08-07 | 2022-06-07 | Fresenius Medical Care Holdings, Inc. | Systems and methods for detection of potential health issues |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5622871A (en) * | 1987-04-27 | 1997-04-22 | Unilever Patent Holdings B.V. | Capillary immunoassay and device therefor comprising mobilizable particulate labelled reagents |
| US3635091A (en) * | 1970-08-31 | 1972-01-18 | Frederick D Linzer | Midstream urine specimen and fractional fluid collectors |
| IT1074038B (it) * | 1976-08-05 | 1985-04-17 | Simes | Esteri della epinina |
| US4376110A (en) * | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4357343A (en) * | 1981-06-26 | 1982-11-02 | Baxter Travenol Laboratories, Inc. | Nutritional composition for management of renal failure |
| US4376100A (en) * | 1981-11-23 | 1983-03-08 | The Dow Chemical Company | Lithium halide brine purification |
| US4632901A (en) * | 1984-05-11 | 1986-12-30 | Hybritech Incorporated | Method and apparatus for immunoassays |
| US4640909A (en) * | 1985-05-07 | 1987-02-03 | J. T. Baker Chemical Company | Bonded phase of silica and carboalkoxyalkyl silanes for solid phase extraction |
| US4870007A (en) * | 1987-12-18 | 1989-09-26 | Eastman Kodak Company | Immobilized biotinylated receptor in test device, kit and method for determining a ligand |
| US5939272A (en) * | 1989-01-10 | 1999-08-17 | Biosite Diagnostics Incorporated | Non-competitive threshold ligand-receptor assays |
| US5273743A (en) * | 1990-03-09 | 1993-12-28 | Hybritech Incorporated | Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent |
| JP2912413B2 (ja) * | 1990-03-28 | 1999-06-28 | 東亜医用電子株式会社 | 粒度分布作成方法 |
| US5405832A (en) * | 1991-11-27 | 1995-04-11 | Immtech International Inc. | Method of treating non-streptococcal bacterial infections |
| US5273961A (en) * | 1992-09-22 | 1993-12-28 | Genentech, Inc. | Method of prophylaxis of acute renal failure |
| SE9401351D0 (sv) * | 1994-04-21 | 1994-04-21 | Venge | A method for diagnosis |
| US5552313A (en) * | 1994-11-21 | 1996-09-03 | Kansas University | DNA encoding mouse phosphotriesterase-related protein |
| EP0864086A4 (en) * | 1995-10-02 | 2001-05-02 | Univ Columbia | BIOCHEMICAL MARKERS OF THE ISCHEMY |
| US5750345A (en) * | 1995-10-31 | 1998-05-12 | Evanston Hospital Corporation | Detection of human α-thalassemia mutations and their use as predictors of blood-related disorders |
| US5627034A (en) * | 1995-12-05 | 1997-05-06 | Wisconsin Alumni Research Foundation | Assay for carcinoma proliferative status by measuring NGAL expression level |
| DE69735364T3 (de) * | 1996-05-24 | 2010-05-06 | Biogen Idec Ma Inc., Cambridge | Modulatoren für die regenerierung von gewebe |
| US5945294A (en) * | 1996-11-26 | 1999-08-31 | Heska Corporation | Method to detect IgE |
| JP3334558B2 (ja) * | 1997-04-23 | 2002-10-15 | 富士レビオ株式会社 | 酵素免疫測定方法及び試験片 |
| AU728558B2 (en) * | 1997-04-30 | 2001-01-11 | Maruha Nichiro Seafoods, Inc. | Method for detecting or predicting ischemic diseases |
| WO1999007740A2 (en) * | 1997-08-06 | 1999-02-18 | Zymogenetics, Inc. | Lipocalin homologs |
| US6242246B1 (en) * | 1997-12-15 | 2001-06-05 | Somalogic, Inc. | Nucleic acid ligand diagnostic Biochip |
| US6500627B1 (en) * | 1998-02-03 | 2002-12-31 | The Trustees Of Columbia University In The City Of New York | Methods for predicting pregnancy outcome in a subject by HCG assay |
| US6309888B1 (en) * | 1998-09-04 | 2001-10-30 | Leuven Research & Development Vzw | Detection and determination of the stages of coronary artery disease |
| AUPP784398A0 (en) * | 1998-12-21 | 1999-01-21 | Monash University | Kidney disease detection and treatment |
| US6114123A (en) * | 1999-06-14 | 2000-09-05 | Incyte Pharmaceuticals, Inc. | Lipocalin family protein |
| AU5330200A (en) * | 1999-06-18 | 2001-01-09 | Michigan State University | Method and apparatus for the detection of volatile products in a sample |
| US6762032B1 (en) * | 1999-08-23 | 2004-07-13 | Biocrystal, Ltd. | Compositions, assay kits, and methods for use related to a disease condition comprising multiple sclerosis and/or a pro-MS immune response |
| US20020160495A1 (en) * | 2000-09-20 | 2002-10-31 | University Of Medicine And Dentistry | Soluble ischemia activated protein |
| CA2424431A1 (en) * | 2000-10-03 | 2002-04-11 | Rowett Research Institute | Method of assaying pyrrole-containing biological compounds |
| AU1169702A (en) * | 2000-10-13 | 2002-04-22 | Childrens Medical Center | Non-invasive enzyme screen for tissue remodelling-associated conditions |
| FI20010019A (fi) * | 2001-01-05 | 2002-07-06 | Biohit Oyj | Menetelmä atrofisen diagnostisoimiseksi |
| PT1384075E (pt) * | 2001-03-28 | 2010-03-23 | Heska Corp | Métodos de detecção de doença renal inicial em animais |
| US7713705B2 (en) * | 2002-12-24 | 2010-05-11 | Biosite, Inc. | Markers for differential diagnosis and methods of use thereof |
| US20040203083A1 (en) * | 2001-04-13 | 2004-10-14 | Biosite, Inc. | Use of thrombus precursor protein and monocyte chemoattractant protein as diagnostic and prognostic indicators in vascular diseases |
| DE60235416D1 (de) * | 2001-05-04 | 2010-04-01 | Biosite Inc | Diagnostische Marker der akuten koronaren Syndrome und ihre Verwendungen |
| US6767733B1 (en) * | 2001-10-10 | 2004-07-27 | Pritest, Inc. | Portable biosensor apparatus with controlled flow |
| US6986995B2 (en) * | 2002-02-28 | 2006-01-17 | Prometheus Laboratories, Inc. | Methods of diagnosing liver fibrosis |
| US6847451B2 (en) * | 2002-05-01 | 2005-01-25 | Lifescan, Inc. | Apparatuses and methods for analyte concentration determination |
| GB0215509D0 (en) | 2002-07-04 | 2002-08-14 | Novartis Ag | Marker genes |
| AU2003247303A1 (en) * | 2002-07-17 | 2004-02-02 | Index Pharmaceuticals Ab | Antisense compounds, methods and compositions for treating ngal-related inflammatory disorders |
| CN1417583A (zh) * | 2002-11-27 | 2003-05-14 | 复旦大学 | 一种检测辐射肾性骨矿物盐损伤方法 |
| AU2004225472B2 (en) * | 2003-03-27 | 2011-02-10 | Children's Hospital Medical Center | A method and kit for detecting the early onset of renal tubular cell injury |
| US7776824B2 (en) * | 2004-05-06 | 2010-08-17 | The Trustees Of Columbia University | NGAL for reduction and amelioration of ischemic and nephrotoxic injuries |
| US20050272101A1 (en) * | 2004-06-07 | 2005-12-08 | Prasad Devarajan | Method for the early detection of renal injury |
| ES2818028T3 (es) * | 2004-12-20 | 2021-04-09 | Antibodyshop As | Determinación de lipocalina asociada a gelatinasa de neutrófilos (NGAL) como marcador diagnóstico para trastornos renales |
| WO2007137584A1 (en) * | 2006-05-30 | 2007-12-06 | Antibodyshop A/S | Methods and devices for rapid assessment of severity of injury |
| US8313919B2 (en) * | 2007-03-21 | 2012-11-20 | Bioporto Diagnostics A/S | Diagnostic test for renal injury |
| US7977110B2 (en) * | 2008-06-02 | 2011-07-12 | Children's Hospital Medical Center | Method for distinguishing between kidney dysfunctions |
| US9611305B2 (en) | 2012-01-06 | 2017-04-04 | Mayo Foundation For Medical Education And Research | Treating cardiovascular or renal diseases |
-
2005
- 2005-03-31 US US11/096,113 patent/US20050272101A1/en not_active Abandoned
- 2005-06-07 AT AT05755309T patent/ATE488765T1/de not_active IP Right Cessation
- 2005-06-07 ES ES10186256T patent/ES2717900T3/es active Active
- 2005-06-07 EP EP05755309.1A patent/EP1766395B2/en active Active
- 2005-06-07 CN CN200580026786.3A patent/CN101027556B/zh active Active
- 2005-06-07 EP EP10186256.3A patent/EP2264459B1/en active Active
- 2005-06-07 CA CA2569599A patent/CA2569599C/en active Active
- 2005-06-07 DE DE602005024810T patent/DE602005024810D1/de active Active
- 2005-06-07 AU AU2005253142A patent/AU2005253142B2/en active Active
- 2005-06-07 JP JP2007527645A patent/JP5054525B2/ja active Active
- 2005-06-07 WO PCT/US2005/019951 patent/WO2005121788A2/en active Application Filing
-
2007
- 2007-06-28 US US11/770,372 patent/US20080014604A1/en not_active Abandoned
-
2008
- 2008-12-05 US US12/329,343 patent/US20090142774A1/en not_active Abandoned
-
2009
- 2009-09-25 US US12/567,058 patent/US20100028919A1/en not_active Abandoned
- 2009-10-22 US US12/604,117 patent/US20100047837A1/en not_active Abandoned
-
2010
- 2010-05-21 US US12/785,220 patent/US20110244489A1/en not_active Abandoned
-
2011
- 2011-02-16 US US13/028,309 patent/US20110143456A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20090142774A1 (en) | 2009-06-04 |
| US20100047837A1 (en) | 2010-02-25 |
| ATE488765T1 (de) | 2010-12-15 |
| US20080014604A1 (en) | 2008-01-17 |
| EP1766395B2 (en) | 2018-09-19 |
| EP2264459A3 (en) | 2011-02-16 |
| EP1766395A4 (en) | 2008-03-19 |
| US20050272101A1 (en) | 2005-12-08 |
| US20110244489A1 (en) | 2011-10-06 |
| AU2005253142B2 (en) | 2011-09-29 |
| WO2005121788A2 (en) | 2005-12-22 |
| EP2264459A2 (en) | 2010-12-22 |
| CA2569599C (en) | 2018-10-23 |
| CA2569599A1 (en) | 2005-12-22 |
| DE602005024810D1 (de) | 2010-12-30 |
| US20100028919A1 (en) | 2010-02-04 |
| EP1766395A2 (en) | 2007-03-28 |
| US20110143456A1 (en) | 2011-06-16 |
| CN101027556B (zh) | 2013-03-13 |
| ES2717900T3 (es) | 2019-06-26 |
| WO2005121788A3 (en) | 2006-05-11 |
| JP2008501979A (ja) | 2008-01-24 |
| AU2005253142A1 (en) | 2005-12-22 |
| EP1766395B1 (en) | 2010-11-17 |
| EP2264459B1 (en) | 2019-01-02 |
| CN101027556A (zh) | 2007-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5054525B2 (ja) | 腎疾患および腎損傷の早期発見のための方法 | |
| AU2004225472B2 (en) | A method and kit for detecting the early onset of renal tubular cell injury | |
| JP4879993B2 (ja) | Ｎｇａｌを使用する慢性腎疾患の診断および監視 | |
| JP5755657B2 (ja) | 感受性バイオマーカーとして熱ショックタンパク質７２を用いる、急性腎障害を検出するための診断方法 | |
| WO2007124419A1 (en) | Method and kit for the early detection of impaired renal status | |
| AU2011253624B2 (en) | Method for the early detection of renal disease and injury |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080609 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080711 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20100902 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100907 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20101206 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20101213 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110107 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110117 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20110203 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20110203 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110719 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111018 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111115 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120124 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120703 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120727 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5054525 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150803 Year of fee payment: 3 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |